Total Valuation
CERo Therapeutics Holdings has a market cap or net worth of $755.18K. The enterprise value is -$246.97K.
Market Cap$755.18K
Enterprise Value-$246.97K
Share Statistics
CERo Therapeutics Holdings has 45,112,408 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding45,112,408
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
CERo Therapeutics Holdings’s return on equity (ROE) is 3.66 and return on invested capital (ROIC) is 388.91%.
Return on Equity (ROE)3.66
Return on Assets (ROA)-5.47
Return on Invested Capital (ROIC)388.91%
Return on Capital Employed (ROCE)3.39
Revenue Per Employee0.00
Profits Per Employee-2.49M
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of CERo Therapeutics Holdings is ―. CERo Therapeutics Holdings’s PEG ratio is -0.00001.
PE Ratio―
PS Ratio0.00
PB Ratio-0.05
Price to Fair Value-0.05
Price to FCF-0.02
Price to Operating Cash Flow-0.03
PEG Ratio-0.00001
Income Statement
In the last 12 months, CERo Therapeutics Holdings had revenue of 0.00 and earned -19.92M in profits. Earnings per share was -22.58.
Revenue0.00
Gross Profit-1.09M
Operating Income-18.46M
Pretax Income-19.92M
Net Income-19.92M
EBITDA-17.38M
Earnings Per Share (EPS)-22.58
Cash Flow
In the last 12 months, operating cash flow was -14.40M and capital expenditures -5.00, giving a free cash flow of -14.40M billion.
Operating Cash Flow-14.40M
Free Cash Flow-14.40M
Free Cash Flow per Share-0.32
Dividends & Yields
CERo Therapeutics Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.45
52-Week Price Change-99.83%
50-Day Moving Average0.02
200-Day Moving Average0.62
Relative Strength Index (RSI)74.45
Average Volume (3m)345.42K
Important Dates
CERo Therapeutics Holdings upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
CERo Therapeutics Holdings as a current ratio of 0.30, with Debt / Equity ratio of -6.46%
Current Ratio0.30
Quick Ratio0.30
Debt to Market Cap0.00
Net Debt to EBITDA0.06
Interest Coverage Ratio0.00
Taxes
In the past 12 months, CERo Therapeutics Holdings has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
CERo Therapeutics Holdings EV to EBITDA ratio is 0.04, with an EV/FCF ratio of 0.04.
EV to Sales0.00
EV to EBITDA0.04
EV to Free Cash Flow0.04
EV to Operating Cash Flow0.04
Balance Sheet
CERo Therapeutics Holdings has $857.49K in cash and marketable securities with $598.35K in debt, giving a net cash position of $259.14K billion.
Cash & Marketable Securities$857.49K
Total Debt$598.35K
Net Cash$259.14K
Net Cash Per Share<$0.01
Tangible Book Value Per Share-$1.29
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for CERo Therapeutics Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast85.30%